《生命科学》 2022, 34(7): 806-814

LncRNA UCA1在肿瘤诊断中的研究进展

王思宇¹ , 王　宇^2,*

¹陕西中医药大学基础医学院，咸阳 712046 ²陕西中医药大学医学科研实验中心，咸阳 712046

摘　要：

肿瘤是人类死亡的主要原因之一。现有的肿瘤诊断方法多具有侵袭性，且部分肿瘤标志物的敏感性较低。大量研究发现，长链非编码RNA (long non-coding RNA, lncRNA) 尿路上皮癌胚抗原1 (urothelial carcinoma antigen 1, UCA1) 在膀胱癌、胃癌、结直肠癌和肝癌等多种肿瘤中具有诊断价值，具有较高的敏感性和特异性。此外，在与其他临床常用的肿瘤标志物或肿瘤检测方法联合应用时，UCA1 可提高其诊断效果。该文总结了UCA1 在肿瘤诊断中的相关研究进展，并展望其临床应用前景。

 

通讯作者：王　宇 , Email:wangyu541ban@sina.com

Research progress of lncRNA UCA1 in tumor diagnosis

WANG Si-Yu¹ , WANG Yu^2,*

¹School of Basic Medicine, Shaanxi University of Chinese Medicine, Xianyang 712046, China ²Medical Research Experimental Center, Shaanxi University of Chinese Medicine, Xianyang 712046, China

Abstract:

Tumor is one of the main death reasons for human being. Existing tumor diagnostic methods are mostly invasive, and some tumor markers have low sensitivity. Numerous studies have shown that long non-coding RNA (lncRNA) urothelial carcinoma antigen 1 (UCA1) has diagnostic value in bladder cancer, gastric cancer, colorectal cancer and liver cancer, with high sensitivity and specificity. Moreover, UCA1 can improve its diagnostic effect and level when combined with other commonly used clinical tumor markers or tumor detection methods. This review summarizes the research progress of UCA1 in tumor diagnosis, and prospects for clinical application.

Communication Author：WANG Yu , Email:wangyu541ban@sina.com